**10. References**

Abel, E. A., DiCicco, L. M., Orenberg, E. K., Fraki, J. E., & Farber, E. M. (1986). Drugs in exacerbation of psoriasis. *J Am Acad Dermatol,* 15, 5 Pt 1, (Nov 1986), 1007–22.

The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients 259

Biedermann, T., Röcken, M., & Carballido, J. M. (2004). TH1 and TH2 lymphocyte

Blauvelt, A. (2008). T-helper 17 cells in psoriatic plaques and additional genetic links

Boker, A., Kimball, A. B., & Rolz-Cruz, G. (2007). Biologicals in the treatment of psoriasis.

Bonish, B., Jullien, D., Dutronc, Y., Huang, B. B., Modlin, R., Spada, F. M., Porcelli, S. A., &

Bosani, M., Ardizzone, S., & Porro, G. B. (2009). Biologic targeting in the treatment of inflammatory bowel diseases. *Biologics*, 3, (Jul 2009), 77–97, 1177-5475 Boulton, J. G., & Bourne, J. T. (2007). Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis. *Rheumatology*, 46, 1, (Jan 2007), 178–179, 1462-0324 Bourne, T., Fossati, G., & Nesbitt, A. (2008). A PEGylated Fab' fragment against tumor

Bovenschen, H. J., Gerritsen, W. J., van Rens, D. W., Seyger, M. M., de Jong, E. M., & van de

Bowcock, A. M., & Krueger, J. G. (2005). Getting under the skin: the immunogenetics of

Brandrup, F., Hauge, M., Henningsen, K., & Eriksen, B. (1978). Psoriasis in an unselected series of twins. *Arch Dermatol,* 114, 6, (Jun 1978), 874–878, 0003-987X Brewerton, D. A., Caffrey, M., Nicholls, A., Walters, D., & James, D. C. (1974). HL-A 27 and

Cameron, A. L., Kirby, B., & Griffiths, C. E. (2003). Circulating natural killer cells in

Cameron, A. L., Kirby, B., Fei, W., & Griffiths, C. E. (2002). Natural killer and natural killer-T

Capon, F., Bijlmakers, M. J., Wolf, N., Quaranta, M., Huffmeier, U., Allen, M., Timms, K.,

Chan, J. R., Blumenschein, W., Murphy, E., Diveu, C., Wiekowski, M., Abbondanzo, S.,

*Curr Opin Invest Drugs,* 8, 11, (Nov 2007), 939–946, 1472-4472

*USA*, 95, 17, (Aug 1998), 9979–9984, 0027-8424

*Invest Dermatol*, 9, 1, (Jan 2004), 5–14, 0022-202X

action. *BioDrugs* 22, 5, (2008), 331–337, 1173-8804

psoriasis. *Arch Dermatol Res*, 298, 9, (Feb 2007), 457–463

psoriasis. *Nat Rev Immunol*, 5, 9, (Sept 2005), 699–711, 1474-1733

psoriasis. *Br J Dermatol*, 149, 1, (Jun 2003), 160–164, 0007-0963

cells in psoriasis. *Arch Dermatol Res*, 294, 8, (Nov 2002), 363–369

2000), 4076–4085, 0022-1767

1974), 956–958, 0140-6736

(Sep 2007), 201–6

susceptibility candidate loci in human autoimmune diseases. *Proc Natl Acad Sci* 

development and regulation of TH cell mediated immune responses of the skin. *J* 

between IL-23 and psoriasis. *J Invest Dermatol*, 128, 5, (May 2008), 1064-7, 0022-202X

Nickoloff, B. J. (2000). Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. *J Immunol*, 165, 7, (Oct

necrosis factor for the treatment of Crohn's disease: exploring a new mechanism of

Kerkhof, P. C. (2007). Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for

arthropaties associated with ulcerative colitis and psoriasis. *Lancet*, 1, 7864, (May

Abkevich, V., Gutin, A., Smith, R., Warren, R. B., Young, H. S., Worthington, J., Burden, A. D., Griffiths, C. E., Hayday, A., Nestle, F. O., Reis, A., Lanchbury, J., Barker, J. N., & Trembath, R. C. (2008). Identification of ZNF313/ RNF114 as a novel psoriasis susceptibility gene. *Hum Mol Genet*, 17, 13, (Jul 2008), 1938–45 Capon, F., Di Meglio, P., Szaub, J., Prescott, N. J., Dunster, C., Baumber, L., Timms, K.,

Gutin, A., Abkevic, V., Burden, A. D., Lanchbury, J., Barker, J. N., Trembath, R. C., & Nestle, F. O. (2007). Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. *Hum Genet*, 122, 2,

Lucian, L., Geissler, R., Brodie, S., Kimball, A. B., Gorman, D. M., Smith, K., de


Abrams, J. R., Kelley, S. L., Hayes, E., Kikuchi, T., Brown, M. J., Kang, S., Lebwohl, M. G.,

Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S.,

with psoriasis vulgaris*. J Clin Invest*, 103, 9, (May 1999), 1243–52, 0021-9738 Abu-Amer, Y., Erdmann, J., Alexopoulou, L., Kollias, G., Ross, F. P., & Teitelbaum, S. L.

osteoclastogenesis. *J Biol Chem*, 275, 35, (Sep 2000), 27307–27310, 0021-9258 Alberti, K. G., Zimmet, P., & Shaw, J. (2006). Metabolic syndrome – a new world wide

Ali, Y., Tom, B. D. M., Schentag, C. T., Farewell, V. T., & Gladman, D. D. (2007). Improved

Annacker, O., Asseman, C., Read, S., & Powrie, F. (2003). Interleukin-10 in the regulation of

Antoni, C. E., Kavanaugh, A., van der Heijde, D., Beutler, A., Keenan, G., Zhou, B., Kirkham,

Arican, O., Aral, M., Sasmaz, S., & Ciragil, P. (2005). Serumlevels of TNFalpha, IFN-gamma,

Baker, B. S., Griffiths, C. E., Lambert, S., Powles, A. V., Leonard, J. N., Valdimarsson, H.,&

populations in psoriasis. *Br J Dermatol*, 116, 4, (Apr 1987), 503–10, 0007-0963 Barnes, T., & Moots, R. (2007). Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol. *Inter J Nanomed,* 2, 1, (2007), 3–7, 1176-9114 Baron, R., & Rawadi, G. (2007). Targeting the Wnt/BCatenin pathway to regulate bone

Becker, K. G., Simon, R. M., Bailey-Wilson, J. E., Freidlin, B., Biddison, W. E., McFarland, H.

with disease severity. *Mediators Inflamm* , 2005, 5, (Oct 2005), 273–279, Baadsgaard, O., Salvo, B., Mannie, A., Dass, B., Fox, D. A., & Cooper, K. D. (1990). In vivo

*Med*, 192, 5, (Sep 2000), 681–93, 0022-1007

*Diabet Med*, 23, 5, (May 2006), 469–480, 1262-3636

T cell-induced colitis. *J Autoimmun*, 20, 4, (Jun 2003), 277–9

2007), 2708–2714, 0004-3591

35, 5, (May 2008), 569–876, 0315-162X

2854–61, 0022-1767

7227

Guzzo, C. A., Jegasothy, B. V., Linsley, P. S., & Krueger, J. G. (2000). Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4 immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. *J Exp* 

Menter, A., Lowe, N. J., Krueger, G., Brown, M. J., Weiner, R. S., Birkhofer, M. J., Warner, G. L., Berry, K. K., Linsley, P. S., Krueger, J. G., Ochs, H. D., Kelley, S. L., & Kang, S. (1999), CTLA4 Igmediated blockade of T-cell costimulation in patients

(2000). Tumor necrosis factor receptors types 1 and 2 differentially regulate

definition. A Consensus Statement from the International Diabetes Federation.

survival in psoriatic arthritis (PsA) with calendar time. *Arthritis Rheum*, 56, 8, (Aug

B., Tutuncu, Z., Burmester, G. R., Schneider, U., Furst, D. E., Molitor, J., Keystone, E., Gladman, D. D., Manger, B., Wassenberg, S., Weier, R., Wallace, D. J., Weisman, M. H., Kalden, J. R., & Smolen, J. S. (2008). Two-year efficacy and safety of infliximab treatment in patientswith active psoriatic arthritis: findings of the Infliximab MultinationalPsoriatic Arthritis Controlled Trial (IMPACT). *J Rheumatol*,

IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation

ultraviolet-exposed human epidermal cells activate T suppressor cell pathways that involve CD4+CD45RA+ suppressor-inducer T cells. *J Immunol*, 145, 9, (Nov 1990),

Fry, L. (1987), The effects of cyclosporin A on T lymphocyte and dendritic cell sub-

formation in the adult skeleton. *Endocrinology*, 148, 6, (Jun 2007), 2635–2643, 0013-

F., & Trent, J. M. (1998). Clustering of non-major histocompatibility complex

susceptibility candidate loci in human autoimmune diseases. *Proc Natl Acad Sci USA*, 95, 17, (Aug 1998), 9979–9984, 0027-8424


The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients 261

Elder, J. T., Bruce, A. T., Gudjonsson, J. E., Johnston, A., Stuart, P. E., Tejasvi, T., Voorhees, J.

EMEA. (2009). European Medicines Agency recommends suspension of the marketing

Eyre, R. W., & Krueger, G. G. (1984). The Koebner response in psoriasis, In: *Psoriasis*, Roenigk, H. H., Maibach, H. I., 105-116, Marcel Dekker, 0824772954, New York Fan, X., Yang, S., Sun, L. D., Liang, Y. H., Gao, M., Zhang, K. Y., Huang, W., & Zhang, X.

FDA. (2009). (2009). FDA statement on the voluntary withdrawal of raptiva from the US

FitzGerald, O., & Winchester, R. (2009). Psoriatic arthritis: from pathogenesis to therapy.

Fleischmajer, R., Kuroda, K., Hazan, R., Gordon, R. E., Lebwohl, M. G., Sapadin, A. N.,

Fredriksson, T., & Pettersson, U. (1978). Severe psoriasis – oral therapy with a new retinoid.

Gallucci, S., Lolkema, M., & Matzinger, P. (1999). Natural adjuvants: endogenous activators

Gaspari, A. A. (2006). Innate and adaptive immunity and the pathophysiology of psoriasis. *J* 

Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006).

Gerdes, S., & Mrowietz, U. (2009). Impact of comorbidities on the management of psoriasis.

Gisondi, P., Girolomoni, G., Sampogna, F., Tabolli, S., & Albeni, D. (2005). Prevalence of

Risk of myocardial infarction in patients with psoriasis. *JAMA*, 296, 14, (Oct 2006),

psoriatic arthritis and joints complaints in a large population of Italian patients hospitalized for psoriasis. *Eur J Dermatol*, 15, 4, (Jul-Aug 2005), 279–283, 1167-1122

TIMP-2. *J Invest Dermatol*, 115, 5, (Nov 2000), 771–7, 0022-202X

of dendritic cells. *Nat Med*, 5,11, (Nov 1999), 1249–55, 1078-8956

314, 5804, (Dec 2006), 1461–1463, 0036-8075

*Exp Immunol*, 96, 1, (Apr 1994), 146–151, 0009-9104

*Arthritis Res Ther,* 11, 1, (Feb 2009), 214, 1478-6362

*Dermatologica,*157, 4, (1978), 238–244, 0011-9059

*Am Acad Dermatol*, 54, 3, (Mar 2006), 67–80

*Curr Probl Dermatol,* 38, (Jul 2009), 21–36

en.pdf>

0001-5555

2009/NEW01992.html>

1735–1741, 0098-7484

H., Targan, S., Datta, L. W., Kistner, E. O., Schumm, L. P., Lee, A. T., Gregersen, P. K., Barmada, M. M., Rotter, J. I., Nicolae, D. L., & Cho, J. H. (2006). A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science*,

J., Abecasis, G. R., & Nair, R. P. (2010). Molecular dissection of psoriasis: integrating genetics and biology. *J Invest Dermatol*, 130, 5, (May 2010), 1213-26, 0022-202X EMEA. (2008). Refusal assessment report for CIMZIA. Procedure No. EMEA/H/C/740. 19

March 2008, available from: <http://www.emea.europa.eu/humandocs/PDFs/EPAR/cimzia/H-740-RAR-

authorisation of Raptiva (efalizumab). 19 February 2009, available from: <http:// www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/20855709en.pdf > Ettehadi, P., Greaves, M. W., Wallach, D., Aderka, D., & Camp, R. D. (1994). Elevated tumor

necrosis factor-alpha (TNF alpha) biological activity in psoriatic skin lesions. *Clin* 

(2007). Comparison of clinical features of HLA-Cw\*0602-positive and-negative psoriasis patients in a Han Chinese population. *Acta Derm Venereol,* 87, 4, 335–40,

market. 8 April 2009, available from: <http://www.fda.gov/bbs/topics/NEWS/

Unda, F., Iehara, N., & Yamada, Y. (2000). Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor

Waal Malefyt, R., Kastelein, R. A., McClanahan, T. K., & Bowman, E. P. (2006). IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. *J Exp Med*, 203, 12, (Nov 2006), 2577– 87, 0022-1007


Chan, W. L., Pejnovic, N., Liew, T. V., Lee, C. A., Groves, R., & Hamilton, H. (2003). NKT

Clark, R. A., & Kupper, T. S. (2006). Misbehaving macrophages in the pathogenesis of

Cohen, A. D., Dreiher, J., & Birkenfeld, S. (2009). Psoriasis associated with ulcerative colitis and Crohn's disease. *J Eur Acad Dermatol Venereol*, 23, 5, (May 2009), 561–565 Conrad, C., Boyman, O., Tonel, G., Tun-Kyi, A., Laggner, U., de Fougerolles, A., Kotelianski,

Curry, J. L., Qin, J. Z., Robinson, J., & Nickoloff, B. J. (2003). Reactivity of resident

Dahlqvist, S. R., Engstrand, S., Berglin, E., & Johnson, O. (2004). Conversion towards an

D'Elios, M. M., Del Prete, G., & Amedei, A. (2010). Targeting IL-23 in human diseases. *Expert* 

Detmar, M., Brown, L. F., Claffey, K. P., Yeo, K. T., Kocher, O., Jackman, R. W.,. Berse, B., &

Di Cesare, A., Di Meglio, P., & Nestle, F. O. (2009). The IL-23/Th17 Axis in the

Diarra, D., Stolina, M., Polzer, K., Zwerina, J., Ominsky, M. S., Dwyer, D., Korb, A., Smolen,

Ding, C., Xu, J., & Li, J. (2008). ABT-874, a fully human monoclonal anti IL-12/IL-23

Djemadji-Oudjiel, N., Goerdt, S., Kodelja, V., Schmuth, M., & Orfanos, C. E. (1996).

Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart,

remodeling. *Nat Med*, 13, 2, (Feb 2007), 156–163. 20, 1078-8956

system. *Arch Pathol Lab Med,* 127, 3, (Mar 2003), 289–296, 0003-9985

infliximab therapy. *Scand J Rheumatol*, 35, 2, (Mar-Apr 2004), 107–111 De Filippis, L. G., Caliri, A., Lo Gullo, R., Bartolone, S. , Miceli, G., Cannavò, S. P., Borgia, F.,

psoriasis. *J Clin Invest* 116, 8, (Aug 2006), 2084–7, 0021-9738

87, 0022-1007

0165-2478

(Jun 2007), 836–42, 1078-8956

1141–6, 0022-1007

0022-202X

*Tissue React*, 27, 4 (2005), 159–162, 0250-0868

*Drugs* 9, 5, (May 2008), 515–522, 1472-4472

288, 12, (Nov 1996), 757–64

*Opin Ther Targets*, 14, 7, (Jul 2010), 759-74, 1472-8222

Waal Malefyt, R., Kastelein, R. A., McClanahan, T. K., & Bowman, E. P. (2006). IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. *J Exp Med*, 203, 12, (Nov 2006), 2577–

cell subsets in infection and inflammation. *Immunol Lett*, 85, 2, (Jan 2003), 159–163,

V., Gardner, H., & Nestle, F. O. (2007). Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. *Nat Med*, 13, 7,

immunocytes in normal and prepsoriatic skin using an ex vivo skin-explant model

atherogenic lipid profile in rheumatoid arthritis patients during long-term

Basile, G., Aloisi, G., Zimbaro, G., Scribano, E., & Bagnato, G. F. (2005). Ultrasonography in the early diagnosis of psoriasis-associated enthesopathy. *Int J* 

Dvorak, H. F. (1994). Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. *J Exp Med* 180, 3, (Sep 1994),

Immunopathogenesis of Psoriasis. *J Invest Dermatol*, 129, 6, (Jun 2009), 1339–50,

J., Hoffmann, M., Scheinecker, C., van der Heide, D., Landewe, R., Lacey, D., Richards, W. G., & Schett, G. (2007). Dickkopf-1 is a master regulator of joint

antibody for the potential treatment of autoimmune diseases. *Curr Opin Investig* 

Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+3, MS-1+/\_, 25F9-) in psoriatic dermis. *Arch Dermatol Res*,

A. H., Abraham, C., Regueiro, M., Griffiths, A., Dassopoulos, T., Bitton, A., Yang,

H., Targan, S., Datta, L. W., Kistner, E. O., Schumm, L. P., Lee, A. T., Gregersen, P. K., Barmada, M. M., Rotter, J. I., Nicolae, D. L., & Cho, J. H. (2006). A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science*, 314, 5804, (Dec 2006), 1461–1463, 0036-8075


The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients 263

Griffiths, C. E., Christophers, E., Barker, J. N., Chalmers, R. J., Chimenti, S., Krueger, G. G.,

Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A.,

Gudjonsson, J. E., Johnston, A., Sigmundsdottir, H., & Valdimarsson, H. (2004).

Gudjonsson, J. E., Karason, A., Runarsdottir, E. H., Antonsdottir, A. A., Hauksson, V. B.,

Gupta, M. A., Gupta, A. K., Kirkby, S., Schork, N. J., Gorr, S. K., Ellis, C. N., & Voorhees, J. J.

Haider, A. S., Duculan, J., Whynot, J. A., & Krueger, J. G. (2006). Increased JunB mRNA and

Haider, A. S., Lowes, M. A., Suárez-Farinas, M., Zaba, L. C., Cardinale, I., Khatcherian, A.,

Henseler, T., & Christophers, E. (1985). Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. *J Am Acad Dermatol,* 13, 3, (Sept 1985), 450–6 Henseler, T., & Christophers, E. (1995). Disease concomitance in psoriasis. *J Am Acad* 

Hensen, P., Windemuth, C., Hüffmeier, U., Rüschendorf, F., Stadelmann, A., Hoppe, V.,

Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D.,

Hüffmaier, U., Lascorz, J., Böhm, B., Lohmann, J., Wendler, J., Mössner, R., Reich, K.,

Fenneker, D., Ständer, M., Schmitt-Egenolf, M., Wienker, T. F., Traupe, H., & Reis, A. (2003). Association scan of the novel psoriasis susceptibility region on chromosome 19: evidence for both susceptible and protective loci. *Exp Dermatol*,

Yancopoulos, G. D., & Wiegand, S. J. (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. *Science,* 284, 5422, (Jun

Traupe, H., Kurrat, W., Burkhardt, H., & Reis, A. (2009). Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. *J Invest Dermatol,* 129, 2, (Feb 2009), 355–358, 0022-

study of 127 patients. *Gen Hosp Psychiatry,* 11, 3, (May 1989), 166–73

*Circulation*, 112, 17, (Oct 2005), 2735–2752, 0009-7322

126, 4, (Apr 2006), 740–5, 0022-202X

1–8, 0009-9104

912–4, 0022-202X

2008), 1913–20, 0022-1767

12,4, (Aug 2003), 490–6

1999), 1994–8, 0036-8075

202X

*Dermatol*, 32, 6, (Jun 1995), 982–986

Leonardi, C., Menter, A., Ortonne, J. P., & Fry, L. (2007). A classification of psoriasis vulgaris according to phenotype. *Br J Dermatol,* G, 2, (Feb 2007), 258–262, 0007-0963

Gordon, D. J., Krauss, R. M., Savage, P. J., Smith. S. C. Jr., Spertus, J. A., Costa, F., American Heart Association, & National Heart, Lung, and Blood Institute. (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

Immunopathogenic mechanisms in psoriasis. *Clin Exp Immunol*, 135, 1, (Jan 2004),

Jonsson, H. H., Gulcher, J., Stefansson, K., & Valdimarsson, H. (2006). Distinct clinical differences between HLA-Cw\*0602 positive and negative psoriasis patients–an analysis of 1019 HLA-C- and HLA-B-typed patients. *J Invest Dermatol*,

(1989). A psychocutaneous profile of psoriasis patients who are stress reactors. A

protein expression in psoriasis vulgaris lesions. *J Invest Dermatol*, 126, 4, (Apr 2006),

Novitskaya, I., Wittkowski, K. M., & Krueger, J. G. (2008). Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthaseproducing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. *J Immunol*, 180, 3, (Feb


Gisondi, P., Tinazzi, I., El-Dalati, G., Gallo, M., Biasi, D., Barbara, L. M., & Girolomoni, G.

Gladman, D. D. (2009). Psoriatic arthritis. *Dermatol Ther,* 22, 1, (Jan-Feb 2009), 40–55, 1396-

Gladman, D. D., Farewell, V. T., Husted, J., & Wong, K. (1998). Mortality studies in psoriatic

Gladman, D. D., Stafford-Brady, F., Chang, C. H., Lewandowski, K., & Russell, M. L. (1990).

Gondek, D. C., Lu, L. F., Quezada, S. A., Sakaguchi, S., & Noelle, R. J. (2005). Cutting edge:

Gordon, K. B., Vaishnaw, A. K., O'Gorman, J., Haney, J., Menter, A., & Alefacept Clinical

Gottlieb, A. B., Chamian, F., Masud, S., Cardinale, I., Abello, M. V., Lowes, M. A., Chen, F.,

Gottlieb, A. B., Cooper, K. D., McCormick, T. S., Toichi, E., Everitt, D. E., Frederick, B., Zhu,

Gottlieb, A. B., Mease, P. J., Mark Jackson, J., Eisen, D., Amy Xia, H., Asare, C., & Stevens, S.

Gottlieb, A., Menter, A., Mendelsohn, A., Shen, Y. K., Li, S., Guzzo, C., Fretzin, S., Kunynetz,

Gottlieb, S. L., Gilleaudeau, P., Johnson, R., Estes, L., Woodworth, T. G., Gottlieb, A. B., &

Griffiths, C. E. M., Strober, B., van de Kerkhof, P. C. M., Ho, V., Guzzo, C., Yeilding, N.

Griffiths, C. E., & Barker, J. N. (2007). Pathogenesis and clinical features of psoriasis. *Lancet,* 

dermatologists' office. *J Dermatolog Treat*, 17, 5, (2006), 279–287

crossover trial. *Lancet*, 373, 9664, (Feb 2009), 633–40, 0140-6736

*Arthritis Rheum*, 41, 6, (Jun 1998), 1103–1110, 0004-3591

*Rheumatol*, 17, 6, (Jun 1990), 809–812, 0315-162X

*Curr Med Res Opin,* 23, 5, (May 2007), 1081–1092

*Nat Med*, 1, 5, (May 1995), 442–7, 1078-8956

370, 9583, (Jul 2007), 263–271, 0140-6736

26–30, 0003-4967

2005), 1783–6, 0022-1767

2003), 1563–1570, 0003-987X

2005), 2721–9, 0022-1767

2008.

0296

(2008). Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropaty: a hospital-based case-control study. *Ann Rheum Dis*, 67, 1, (Jan 2008),

arthritis. Results from a single centre. II. Prognostic indicators for mortality.

Longitudinal study of clinical and radiological progression in psoriatic arthritis. *J* 

contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. *J Immunol*, 174, 4, (Feb

Study Group. (2003). Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T cell counts. *Arch Dermatol* 139, 12, (Dec

Magliocco, M., & Krueger, J. G. (2005). TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. *J Immunol*, 175, 4, (Aug

Y., Pendley, C. E., Graham, M. A., & Mascelli, M. A. (2007). A phase 1, doubleblind, placebo-controlled study evaluating single subcutaneous administration of human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis.

R. (2006). Clinical characteristics of psoriatic arthritis and psoriasis in

R., Kavanaugh, A. (2009). Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebocontrolled,

Krueger, J. G. (1995). Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis.

(2008). A phase 3 multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis. Proceedings of European Academy of Dermatology and Venerology Annual Congress Paris, July


The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients 265

Koreck, A., Sura´nyi, A., Szo¨ny, B. J., Farkas, A., Bata-Csörgö, Z., Kemény, L., & Dobozy, A.

Krueger, G. G., Bergstresser, P. R., Lowe, N. J., Voorhees, J. J., & Weinstein, G. D. Psoriasis.

Krueger, G. G., Langley, R. G., Leonardi, C., Yeilding, N., Guzzo, C., Wang, Y., Dooley, L. T.,

Krueger, J. G. (2002). The immunologic basis for the treatment of psoriasis with new biologic

Kuroda, K., Sapadin, A., Shoji, T., Fleischmajer, R., & Lebwohl, M. (2001). Altered expression

Langewouters, A. M., van Erp, P. E., de Jong, E. M., & van de Kerkhof, P. C. (2008).

mild plaque psoriasis. *Arch Dermatol Res* 2008; 300, 3, (Mar 2008), 107–113 Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D.,

Larsen, R., Ryder, L. P., Svejgaard, A., & Gniadecki, R. (2007). Changes in circulating

Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley,

Liao, Y. H., Jee, S. H., Sheu, B. C., Huang, Y. L., Tseng, M. P., Hsu, S. M., & Tsai, T. F. (2006).

Lima, X. T., Seidler, E. M., Lima, H. C., & Kimball, A. B. (2009). Long-term safety of biologics in dermatology. *Dermatol Ther,* 22, 1, (Jan-Feb 2009), 2–21, 1396-0296 Mallbris, L., Akre, O., Granath, F., Yin, L., Lindelöf, B., Ekbom, A., & Ståhle-Bäckdahl, M.

Mallon, E., Newson, R., & Bunker, C. B. (1999). HLA-Cw6 and the genetic predisposition to

trial (PHOENIX 1). *Lancet*, 371, 9625, (May 2008), 1665–74, 0140-6736 Lew, W., Bowcock, A. M., & Krueger, J. G. (2004). Psoriasis vulgaris: cutaneous lymphoid

*Trends Immunol*, 25, 6, (Jun 2004), 295–305, 1471-4906

outpatients. *Eur J Epidemiol*, 19, 3, (2004), 225–230

(Oct 1999), 693–5, 0022-202X

psoriasis. *Br J Dermatol*, 155, 2, (Aug 2006), 318–324, 0007-0963

psoriasis. *J Am Acad Dermatol*, 57, 2, (Aug 2007), 347–354

(1984). *J Am Acad Dermatol*, 11, 5, (Nov 1984), 937–47

agents. *J Am Acad Dermatol*, 46, 1, (Jan 2002), 1–23

2007), 580–92, 0028-4793

2005), 233–40, 0022-1007

1, (Jun 2007), 23–30

15, (May 2001), 713–20, 0022-202X

(2002). CD3+CD56+ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis. *Clin Exp Immunol*, 127, 1, (Jan 2002), 176–182, 0009-9104 Kremers, H. M., McEvoy, M. T., Dann, F. J., & Gabriel, S. E. (2007). Heart disease in

Lebwohl, M., & CNTO 1275 Psoriasis Study Group. (2007). A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. *N Engl J Med*, 356, 6, (Feb

of angiopoietins and Tie2 endothelium receptor in psoriasis. *J Invest Dermatol*, 116,

Lymphocyte subsets in peripheral blood of patients with moderate-tosevere versus

McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. *J Exp Med*, 201, 2, (Jan

lymphocyte subpopulations following administration of the leucocyte functionassociated antigen-3 (LFA-3)/IgG1 fusion protein alefacept. *Clin Exp Immunol*, 149,

L. T., Gordon, K. B., & PHOENIX 1 study investigators. (2008). Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled

tissue supports T-cell activation and "Type 1" inflammatory gene expression.

Increased expression of the natural killer cell inhibitory receptor CD94/NKG2A and CD158b on circulating and lesional T cells in patients with chronic plaque

(2004). Increased risk for cardiovascular mortality in psoriasis inpatients but not in

psoriasis: a metaanalysis of published serologic studies. *J Invest Dermatol*, 113, 4,


Huvers, F. C., Popa, C., Netea, M. G., van den Hoogen, F. H., & Tack, C. J. (2007). Improved

Irace, C. ,Mancuso, G., Fiaschi, E., Madia, A., Sesti, G., & Gnasso, A. (2004). Effect of anti

Jablonska, S. (1986). Immunological mechanisms in psoriasis: role of polymorphonuclear

Jegasothy, B. V., Ackerman, C. D., Todo, S., Fung, J. J., Abu-Elmagd, K., & Starzl, T. E. (1992).

Johnson, L. W., & Weinstock, R. S. (2006). The metabolic syndrome: concepts and controversy. *Mayo Clin Proc*, 81, 12, (Dec 2006), 1615–1620, 0025-6196 Kana, D., Stafford, L., Bresniham, B., & Fitzgerald, O. (2003). A prospective, clinical and

Katz, H. I., Waalen, J., & Leach, E. E. (1994). Acitretin in psoriasis: an overview of adverse

Kauffman, C. L., Aria, N., Toichi, E., McCormick, T. S., Cooper, K. D., Gottlieb, A. B., Everitt,

Kavanaugh, A., McInnes, I., Mease, P., Krueger, G. G., Gladman, D., Gomez- Reino, J. Papp,

Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., & Kollias, G.

Kimball, A. B., Gladman, D., Gelfand, J.M., Gordon, K., Horn, E. J., Korman, N. J., Korver,

Kimball, A. B., Gordon, K. B., Langley, R. G., Menter, A., Chartash, E. K., & Valdes, J.

Kimball, A. B., Robinson, D. Jr., Wu, Y., Yeilding, N., Paramore, C., Fraeman, K., & Bala, M.

genetic model of arthritis. *EMBO J*, 10, 13 (Dec 1991), 4025–4031

diseases. *Ann Rheum Dis*, 66, 4, (Apr 2007), 558–559, 0003-4967

*Atherosclerosis*, 177, 1, (Nov 2004), 113–118, 0021-9150

*Rheumatology*, 42, 12, (Dec 2003), 1460–1468, 1462-0324

*Dermatol*, 123, 6, (Dec 2004), 1037–44, 0022-202X

(Apr 2009), 976– 986, 0003-4967

144, 2, (Feb 2008), 200–7, 0003-987X

2008), 1031–1042

effects. *J Am Acad Dermatol*, 41, 3 Pt 2, (Sep 1994), S7–S12

*Dermatol*, 128, 6, (Jun 1992), 781–5, 0003-987X

Elsevier, 0444012125, New York

insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic

TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol.

leukocytes, In: *Psoriasis,* Farber, E. M., Nall, L., Morhenn, V., & Jacobs, P. H., 131-7,

Tacrolimus (FK 506)–a new therapeutic agent for severe recalcitrant psoriasis. *Arch* 

radiological study of early psoriatic arthritis: an early synovitis clinic experience.

D. E., Frederick, B., Zhu, Y., Graham, M. A., Pendley, C. E., & Mascelli, M. A. (2004). A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. *J Invest* 

K., Zrubek, J., Mudivarthy, S., Mack, M., Visvanathan, S., & Beutler, A. (2009). Golimumab, a new human tumor necrosis factor a, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. *Arthritis Rheum,* 60, 4,

(1991). Transgenic mice expression human tumor necrosis factor: a predictive

G., Krueger, G. G., Strober, B. E., Lebwohl, M. G., & National Psoriasis Foundation. (2008a). National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. *J Am Acad Dermatol,* 58, 6, (Jun

(2008b). Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. *Arch Dermatol*,

(2008c). Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. *Dermatology*, 217, 1, (Mar 2008), 27–37, 1018-8665


The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients 267

Najarian, D. J., & Gottlieb, A. B. (2003). Connections between psoriasis and Crohn's disease.

Nakamura, K., Kitani, A., Fuss, I., Pedersen, A., Harada, N., Nawata, H., & Strober, W.

Namazi, M. R. (2004). Paradoxical exacerbation of psoriasis in AIDS: proposed explanations

Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., Troxel, A. B., & Gelfand, J. M. (2006).

Nestle, F. O., Kaplan, D. H., & Barker, J. (2009). Psoriasis. *N Engl J Med,* 361, 5, (Jul 2009),

Nickoloff, B. J. (1999a). Skin innate immune system in psoriasis: friend or foe?. *J Clin Invest*,

Nickoloff, B. J., & Nestle, F. O. (2004). Recent insights into the immunopathogenesis of

Nickoloff, B. J., Bonish, B., Huang, B. B., & Porcelli, S. A. (2000). Characterization of a T cell

mouse model system. *J Dermatol Sci*, 24, 3, (Dec 2000), 212–225, 0923-1811 Nickoloff, B. J., Karabin, G. D., Barker, J. N., Griffiths, C. E., Sarma, V., Mitra, R. S., Elder, J.

Nickoloff, B. J., Qin, J. Z., & Nestle, F. O. (2007a). Immunopathogenesis of psoriasis. *Clinic* 

Nickoloff, B. J., Wrone-Smith, T., Bonish, B., & Porcelli, S. A. (1999b). Response of murine

Nickoloff, B. J., Xin, H., Nestle, F. O., & Qin, J. Z. (2007b). The cytokine and chemokine network in psoriasis. *Clin Dermatol* 25, 6, (Nov-Dec 2007), 568–573, 0738-081X Nograles, K. E., Brasington, R.D., & Bowcock, A. M. (2009). New insights into the

O'Neill, J. L., & Kalb, R. E. (2009). Ustekinumab in the therapy of chronic plaque psoriasis.

Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J.,

from IL-12. *Immunity*, 13, 5, (Nov 2000), 715–25, 1074-7613

*Rev Allerg Immunol,* 33, 1-2, (Oct 2007), 45–56, 1080-0549

(2004). TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. *J Immunol*, 172, 2, (Jan 2004),

including the potential roles of substance P and gram-negative bacteria.

Prevalence of cardiovascular risk factors in patients with psoriasis. *J Am Acad* 

psoriasis provide new therapeutic opportunities. *J Clin Invest*, 113, 12, (Jun 2004),

line bearing natural killer receptors and capable of creating psoriasis in a SCID

T., Kunkel, S. L., & Dixit, V. M. (1991). Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. *Am J Pathol*, 138, 1, (Jan 1991),

and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes. Detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. *Arch Dermatol*, 135, 5, (May 1999),

pathogenesis and genetics of psoriatic arthritis. *Nat Clin Pract Rheumatol,* 5, 2, (Feb

Singh, K., Zonin, F., Vaisberg, E., Churakova, T., Liu, M., Gorman, D., Wagner, J., Zurawski, S., Liu, Y., Abrams, J. S., Moore, K. W., Rennick, D., de Waal-Malefyt, R., Hannum, C., Bazan, J. F., & Kastelein, R. A. (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct

*J Am Acad Dermatol*, 48, 6, (Jun 2003), 805–821

*Autoimmunity,* 37, 1, (Feb 2004), 67–71

*Dermatol* 55, 5, (Nov 2006), 829–835

104, 9, (Nov 1999), 1161–4, 0021-9738

834–42, 0022-1767

496–509, 0028-4793

1664–1675, 0021-9738

129–40, 0002-9440

546–552, 0003-987X

2009), 83–91, 1745-8382

*Biologics* 3, (Jul 2009), 159–168, 1177-5475


Marble, D. J., Gordon, K. B., Nickoloff, B. J. (2007). Targeting TNFalpha rapidly reduces

Marra, M., Campanati, A., Testa, R., Sirolla, C., Bonfigli, A. R., Franceschi, C., Marchegiani,

with psoriasis. *Int J Immunopathol Pharmacol*, 20, 4, (Oct-Dec 2007), 731–736 Martin, M. P., Nelson, G., Lee, J. H., Pellett, F., Gao, X., Wade, J., Wilson, M. J., Trowsdale, J.,

specific HLA-C alleles. *J Immunol*, 169, 6, (Sept 2002), 2818–22, 0022-1767 McEwen, C., DiTata, D., Lingg, C., Porini, A., Good, A., & Rankin, T. (1971). Ankylosing

McKenzie, B. S., Kastelein, R. A., & Cua, D. J. (2006). Understanding the IL-23-IL-17 immune

Mease, P. J., Gladman, D. D., & Keystone, E. C. (2006a). Alefacept with methotrexate for the

Mease, P. J., Kivitz, A. J., Burch, F. X., Siegel, E. L., Cohen, S. B., Ory, P., Salonen, D.,

treatment with etanercept. *J Rheumatol*, 33, 4, (Apr 2006), 712–721, 0315-162X Menssen, A., Trommler, P., Vollmer, S., Schendel, D., Albert, E., Gurtler, L., Riethmüller, G.,

Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B.,

Montecucco, C. (2006). Remission, a therapeutic goal in inflammatory arthropathies?

Morris, A., Rogers, M., Fischer, G., & Williams, K. (2001). Childhood psoriasis: a clinical review of 1262 cases. *Pediatr Dermatol*, 18, 3, (May-Jun 2001), 188–98 Mössner, R., Schön, M. P., & Reich, K. (2008). Tumor necrosis factor antagonists in the therapy of psoriasis. *Clin Dermatol* 26, 5, (Sep-Oct 2008), 486–502, 0738-081X Mrowietz, U., Elder, J. T., & Barker, J. (2006). The importance of disease associations and

Nair, R. P., Stuart, P. E., Nistor, I., Hiremagalore, R., Chia, N. V., Jenisch, S., Weichenthal, M.,

pathway. *Trends Immunol*, 27, 1, (Jan 2006), 17–23, 1471-4906

study. *Arthritis Rheum* 54, 5, (May 2006), 1638– 1645, 0004-3591

with biologics. *J Am Acad Dermatol,* 58, 5, (May 2008), 826–850

gene. *Am J Hum Genet,* 78, 5, (May 2006), 827–51, 0002-9297

*Dermatol Res*, 298, 7, (Dec 2006), 309–319

0923-1811

83, 0022-1767

Jun 1971), 291–318, 0004-3591

density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. *J Dermatol Sci*, 48, 2, (Nov 20079, 87–101,

F., & Offidani, A. (2007). Effect of etanercept on insulin sensitivity in nine patients

Gladman, D., & Carrington, M. (2002). Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of

spondylitis and spondylitis accompanying ulcerative colitis, regional enteritis, psoriasis and Reiter's disease. A comparative study. *Arthritis Rheum*, 14, 3, (May-

treatment of psoriatic arthritis: results from a double blind, placebo-controlled

Rubenstein, J., Sharp, J. T., Dunn, M., & Tsuji, W. (2006b). Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of

& Prinz, J. C. (1995). Evidence for an antigenspecific cellular immune response in skin lesions of patients with psoriasis vulgaris. *J Immunol*, 155, 8, (Oct 1995), 4078–

Lebwohl, M. G., Koo, J. Y., Elmets, C. A., Korman, N. J., Beutner, K. R., & Bhushan, R. (2008). Guidelines of care for the management of psoriasis and psoriatic arthritis: section I. Overview of psoriasis and guidelines of care for the treatment of psoriasis

Clinical data from adalimumab studies. *Drugs,* 66, 14, (2006), 1783–1795, 0012-6667

concomitant therapy for the long-term management of psoriasis patients. *Arch* 

Abecasis, G. R., Lim, H. W., Christophers, E., Voorhees, J. J., & Elder, J. T. (2006). Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1


The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients 269

Queiro-Silva, R., Torre-Alonso, J. C., Tinture-Eguren, T., & Lopez-Lagunas, I. (2003). A

Radtke, B., Reich, K., Blome, C., Rustenbach, S., & Augustin, M. (2009). Prevalence and

Reddy, M., Davis, C., Wong, J., Marsters, P., Pendley, C., & Prabhakar, U. (2007).

Reveille, J.D., Conant, M. A., & Duvic, M. (1990). Human immunodeficiency virus-

Ritchlin, C., Haas-Smith, S. A., Hicks, D., Cappuccio, J., Osterland, C. K., & Looney, R. J.

Rizzo, H. L., Kagami, S., Phillips, K. G., Kurtz, S. E., Jacques, S. L., & Blauvelt, A. (2011). IL-

Rogalski, C., Meyer-Hoffert, U., Proksch, E., & Wiedow, O. (2002). Human leukocyte

Rondinone, C. M. (2006). Adipocyte-derived hormones, cytokines, and mediators. *Endocrine*,

Sano, S., Chan, K. S., Carbajal, S., Clifford, J., Peavey, M., Kiguchi, K., Itami, S., Nickoloff, B.

Saphiro, J., Cohen, A. D., David, M., Hodak, E., Chodik, G., Viner, A., Kremer, E., &

Scalon, J. V., Exter, B. P., Steinberg, M., & Jarvis, C. I. (2009). Ustekinumab: treatment of

Smith, R. L., Warren, R. B., Griffiths, C. E. M., & Worthington, J. (2009). Genetic susceptibility to psoriasis: an emerging picture. *Genome Med* 22*,* 1, (Jul 2009), 72 Sobell, J. M., Kalb, R. E., & Weinberg, J. M. (2009). Management of moderate to severe

Song, I. H., Appel, H., Haibel, H., Loddenkemper, C., Braun, J., Sieper, J., & Rudwaleit, M.

continuum?. *Arthritis Rheum,* 33, 10, (Oct 1990), 1574–8, 0004-3591

*Ann Rheum Dis*, 62, 1, (Jan 2003), 68–70, 0003-4967

Pt 1, (Sep 1999), 401–407

(May 2007), 1–11, 0008-8749

(Aug 1998), 1544–1552, 0315-162X

118, 1, (Jan 2002), 49–54, 0022-202X

29, 1, (Feb 2006), 81–90, 0969-711X

11, 1, (Jan 2005), 43–9, 1078-8956

2009), 1456–1465, 1060-0280

629–634

*Immunol,* 186, 3, (Feb 2011), 1495-502, 0022-1767

agents. *J Drugs Dermatol,* 8, 3, (Mar 2009), 230–238

polyarticular onset predicts erosive and deforming disease in psoriatic arthritis.

clinical features of psoriatic arthritis in 2009 patients with psoriasis: results of a German national survey. *J Eur Acad Dermatol Venerol* 23, 6, (Jun 2009), 683–691 Rapp, S. R., Feldman, S.R., Exum, L., Fleischer, A. B., & Reboussin, D. M. (1999). Psoriasis

causes as much disability as other major medical diseases. *J Am Acad Dermatol,* 41, 3

Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12 and IL-23 induced cytokine secretion by CNTO 1275. *Cell Immunol,* 247, 1,

associated psoriasis, psoriatic arthritis, and Reiter's syndrome: a disease

(1998). Patterns of cytokine production in psoriatic synovium. *J Rheumatol,* 25, 8,

23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. *J* 

elastase induces keratinocyte proliferation in vitro and in vivo. *J Invest Dermatol*,

J., & DiGiovanni, J. (2005). Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. *Nat Med*,

Heymann, A. (2007). The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. *J Am Acad Dermatol*, 56, 4, (Apr 2007),

adult moderate to severe chronic plaque psoriasis. *Ann Pharmacother* 43, 9, (Sep

plaque psoriasis (part I): clinical update on T-cell modulators and investigational

(2008). New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. *J Rheumatol*, 35, 3, (Mar 2008), 532–536, 0315-162X


Ortonne, J. P., Tassel, C., & Reich, K. (2007). Efficacy of certolizumab pegol, a PEGylated

Ozcakar, L., Cetin, A., Inanici, F., Kaymal, B., Gurer, C. K., & Kolemen, F. (2005).

Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo,

Pathirana, A., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P. I., Nast, A., Barker, J., Bos, J. D.,

Pisani, M., & Ruocco, V. (1984). 'Twin' psoriasis in monozygotic twins. *Arch Dermatol*, 120,

Piskin, G., Sylva-Steenland, R. M., Bos, J. D., & Teunissen, M. B. (2006). In vitro and in situ

Popa, C., Netea, M. G., Radstake, T., Van der Meer, J. W., Stalenhoef, A. F., van Riel, P. L., &

Prevoo, M. L., van't Hof, M. A., Kuper, H. H., van Leeuwen, M. A., van de Putte, L. B., &

Prinz, J., Braun-Falco, O., Meurer, M., Daddona, P., Reiter, C., Rieber, P., & Riethmüller, G.

Product Monograph. (2008). Stelara (ustekinumab). Janssen-Ortho Inc, Toronto, Ontario.

psoriasis. *Lancet*, 338, 8762, (Aug 1991), 320–1, 0140-6736

expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. *J Immunol*; 176, 3, (Feb 2006), 1908–15, 0022-1767 Piskin, G., Tursen, U., Sylva-Steenland, R. M., Bos, J. D., & Teunissen, M. B. (2004). Clinical

improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers –

Barerra, P. (2005). Influence of antitumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. *Ann Rheum* 

van Riel, P. L. (1995). Modified disease activity scores the include twenty-eight joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum,* 38, 1, (Jan 1995), 44–48, 0004-3591 Prinz, J. C. (2001). Psoriasis vulgaris–a sterile antibacterial skin reaction mediated by cross-

reactive T cells? An immunological view of the pathophysiology of psoriasis. *Clin* 

(1991). Chimaeric CD4 monoclonal antibody in treatment of generalised pustular

vulgaris. *J Eur Acad Dermatol Venerol,* 23, 2, (Oct 2009), 1–70

IL-12, IL-18 and IL-23. *Exp Dermatol*, 13, 12, (Dec 2004), 764–72

*Academy of dermatology and Venerology*, Vienna, Austria, May 2007.

*Dermatol*, 44, 11, (Nov 2005), 930–932, 0011-9059

(May 2008), 1675–84, 0140-6736

11, (Nov 1984),1418–9, 0003-987X

*Dis*, 64, 2, (Feb 2005), 303–305, 0003-4967

*Exp Dermatol*, 26, 4, (Jun 2001), 326–32

Fab' fragment of an anti-TNF-a monoclonal antibody, in patients previously exposed to biologicals. Preliminary results of a randomised, placebo-controlled phase II clinical trial in psoriasis, *Proceedings of the 16th Congress of the European* 

Ultrasonographical evaluation of the Achilles' tendon in psoriasis patients. *Int J* 

C., Hsu, M. C., Wang, Y., Li, S., Dooley, L. T., Reich, K., PHOENIX 2 study investigators. (2008). Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). *Lancet*, 371, 9625,

Burmester, G. R., Chimenti, S., Dubertret, L., Eberlein, B., Erdmann, R., Ferguson, J., Girolomoni, G., Gisondi, P., Giunta, A., Griffiths, C., Hönigsmann, H., Hussain, M., Jobling, R., Karvonen, S. L., Kemeny, L., Kopp, I., Leonardi, C., Maccarone, M., Menter, A., Mrowietz, U., Naldi, L., Nijsten, T., Ortonne, J. P., Orzechowski, H. D., Rantanen, T., Reich, K., Reytan, N., Richards, H., Thio, H. B., van de Kerkhof, P., & Rzany, B. (2009). European S3-Guidelines on the systemic treatment of psoriasis


The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients 271

van den Oord, J. J., & de Wolf-Peeters, C. (1994). Epithelium-lining macrophages in

van der Heijde, D., Kavanaugh, A., Gladmann, D. D., Antoni, C., Krueger, G. G., Guzzo, C.,

van der Vliet, H. J., von Blomberg, B. M., Nishi, N., Reijm, M., Voskuyl, A. E., van

van Lingen, R. G., Ko¨rver, J. E., van de Kerkhof, P. C., Berends, M. A., van Rens, D. W.,

Vissers, W. H., Arndtz, C. H., Muys, L., Van Erp, P. E., de Jong, E. M., & van de Kerkhof, P.

Vissers, W. H., Berends, M., Muys, L., van Erp, P. E., de Jong, E. M., & van de Kerkhof, P. C.

Vissers, W. H., van Vlijmen, I., van Erp, P. E., de Jong, E. M., & van de Kerkhof, P. C. (2008).

Wang, H., Peters, T., Sindrilaru, A., & Scharffetter-Kochanek, K. (2009). Key role of

Willment, J.A., Lin, H. H., Reid, D. M., Taylor, P. R., Williams, D. L., Wong, S. Y., Gordon, S.,

*J Invest Dermatol*, 129, 5, (May 2009), 1100-14, 0022-202X

psoriasis. *Br J Dermatol*, 130, 5, (May 1994), 589–94, 0007-0963

(Jun 2003), 1774–1785, 0016-5085

2698–2707, 0004-3591

148, 1521-6616

859, 0007-0963

112

(Jul 2008), 91–96, 0007-0963

2008), 705–712, 0007-0963

2003), 4569–73, 0022-1767

Deventer, S. J. (2003). Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. *Gastroenterology*, 124, 7,

Zhou, B., Dooley, L. T., de Vlam, K., Geusens, P., Birbara, C., Halter, D., & Beutler, A. (2007). Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. *Arthritis Rheum*, 56, 8, (Aug 2007),

Bodegraven, A. A., Polman, C. H., Rustemeyer, T., Lips, P., van den Eertwegh, A. J., Giaccone, G., Scheper, R. J., & Pinedo, H. M. (2001). Circulating V(alpha24+) Vbeta11+ NKTcell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. *Clin Immunol*, 100, 2, (Aug 2001), 144–

Langewouters, A. M., Boezeman, J. B., Seyger, M. M., & de Jong, E. M. (2008). Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies. *Br J Dermatol*, 159, 1,

C. (2004a). Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. *Br J Dermatol*, 150, 5, (May 2004), 852–

(2004b). The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. *Exp Dermatol*, 13, 2, (Feb 2004), 106–

Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. *Br J Dermatol,* 158, 4, (Apr

macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis.

& Brown, G. D. (2003). Dectin-1 expression and function are enhanced on alternatively activated and GM-CSF-treated macrophages and are negatively regulated by IL-10, dexamethasone, and lipopolysaccharide*. J Immunol*, 171, 9, (Nov


Soubrier, M., Jouanel, P., Mathieu, S., Poujol, D., Claus, D., Dubost, J. J., & Ristori, J. M.

Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003). Tolerogenic dendritic cells.

Stern, R. S., Nijsten, T., Feldman, S. R., Margolis, D. J., & Rolstad, T. (2004). Psoriasis is

Stratis, A., Pasparakis, M., Rupec, R. A., Markur, D., Hartmann, K., Scharffetter-Kochanek,

Strober, B. E., & Menon, K. (2005). Folate supplementation during methotrexate therapy for patients with psoriasis. *J Am Acad Dermatol*, 53, 4, (Oct 2005), 652–659 Sugiyama, H., Gyulai, R., Toichi, E., Garaczi, E., Shimada, S., Stevens, S. R., McCormick, T.

effector T cell proliferation. J Immunol, 174, 1, (Jan 2005), 164–73, 0022-1767 Sugiyama, H., McCormick, T. S., Cooper, K. D., & Korman, N. J. (2008). Alefacept in the treatment of psoriasis. *Clin Dermatol,* 26, 5, (Sep-Oct 2008), 50–58, 0738-081X Taler, S. J., Textor, S. C., Canzanello, V. J., & Schwartz, L. (1999). Cyclosporin-induced

Taniguchi, M., Seino, K., & Nakayama, T. (2003). The NKT cell system: bridging innate and acquired immunity. *Nat Immunol*, 4, 12, (Dec 2003), 1164–5, 1529-2908 Teunissen, M. B. M. (2005). Langerhans cells and other skin dendritic cells, In: *Skin Immune* 

Toichi, E., Tachibana, T., & Furukawa, F. (2000). Rapid improvement of psoriasis vulgaris

Toichi, E., Torres, G., McCormick, T. S., Chang, T., Mascelli, M. A., Kauffmann, C. L., Aria,

Torti, D. C., & Feldman, S. R. (2007). Interleukin-12, interleukin-23, and psoriasis: current

van den Brande, J., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A.,

prospects. *J Am Acad Dermatol,* 57, 6, (Dec 2007), 1059–1068

inflammation. *J Clin Invest*, 116, 8, (Aug 2006), 2094–104, 0021-9738

*Annu Rev Immunol*, 21, (Dec 2003), 685–711

2007), 136–139, 1087-0024

1999), 437–449

Boca Raton CRC Press, 0849319595, FL

2008), 1972–1980, 1007-9327

rheumatoid arthritis. *Joint Bone Spine,* 75, 1, (Jan 2008), 22–24, 1297-319X Spanakis, E., Sidiropoulos, P., Papadakis, J., Ganotakis, E., Katsikas, G., Karvounaris, S.,

162X

(2008). Effects of antitumor necrosis factor therapy on lipid profile in patients with

Bizaki, A., Kritikos, H., & Boumpas, D. T. (2006). Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. *J Rheumatol* 33, 12, (Dec 2006), 2440–2446, 0315-

common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. *J. Invest Dermatol Symp Proc*, G 2, (Mar

K., Peters, T., van Rooijen, N., Krieg, T., & Haase, I. (2006). Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin

S., & Cooper, K. D. (2005). Dysfunctional blood and target tissue CD4+ CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic

hypertension: incidence, pathogenesis and management. *Drug Saf*, 20, 5, (May

*System: Cutaneous Immunology and Clinical Immunodermatology*, Bos, J. D., 123–82,

during drug-induced agranulocytosis. *J Am Acad Dermatol*, 43, 2, (Aug 2000), 391–5

N., Gottlieb, A. B., Everitt, D. E., Frederick, B., Pendley, C. E., & Cooper, K. D. (2006). An anti-IL-12p40 antibody down-regulates type 1cytokines, chemokines, and IL-12/IL-23 in psoriasis. *J Immunol,* 177, 7, (Oct 2006), 4917–4926, 0022-1767 Torres, M. I., & Rios, A. (2008). Current view of the immunopathogenesis in inflammatory

bowel disease and its implications for therapy. *World J Gastroenterol*, 14, 13, (Apr

Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van

Deventer, S. J. (2003). Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. *Gastroenterology*, 124, 7, (Jun 2003), 1774–1785, 0016-5085


**13** 

*Belgium* 

**Infliximab Therapy for Plaque Psoriasis:** 

*Dermatology Department, UCL (Université Catholique de Louvain), Brussels* 

Psoriasis is a disease with frequently severe impairment of quality of life. Traditional therapies (topical treatments, UV, cyclosporine, acitretin, methotrexate...) are widely used but are not always sufficient, and may be poorly tolerated or contra-indicated. Among biologicals, firsts on the European dermatological market were etanercept and infliximab. Alefacept use was restricted to the United States of America. Byafter, adalimumab and

Among all these biotherapies, infliximab is considered a little bit different : known to be one of the most efficient, infliximab treatment requires a mode of administration quite repulsive for some practitioners. It is an intravenous drug, needing a medicalized center of care with good experience and equipment. Infliximab is also known to induce some adverse event,

To verify these sentences, we intended to examine our patient cohort treated by infliximab in our Dermatology Unit, with a retrospective study of the first 50 patients beginning infliximab therapy in our Department (excluding patients in phase II or III clinical trials).






**1. Introduction** 

Aims :

this

Limitations :

evidence

ustekinumab were launched.

particularly infusion hypersensitivity.

discontinuation for adverse events.


treatment : good or bad concept for patient psychology ?

re-introduction : adverse event ? Systematic prevention ?


**The UCL Experience** 

Pierre-Dominique Ghislain

